The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English (UK)
Deutsch
English (UK)
Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab
MS Treatments
Jahr
Publikationsjahr
2024
Autoren
Autorenliste der Publikation
Hersh CM, Pang M, Miller DM, McGinley MP, Hyland M, Ziemssen T, Avila RL.
Verlag
Publisher-Information
Neurodegener Dis Manag. 2024 Apr 16.
Link
Zur Publikation (externer Server)
https://doi.org/10.2217/nmt-2023-0047
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Treatments
MSZ
2024
Change from platform to high efficacy disease-modifying treatment for multiple sclerosis despite NEDA
MS Treatments
Jahr
2024
Rule-Based DSL for Continuous Features and ML Models Selection in Multiple Sclerosis Research
MASC
Jahr
2024
Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis
MS Treatments
Jahr
2024
Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis
MS Treatments
Jahr
2024
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study
MS Treatments
Jahr
2024